These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 9316394)

  • 1. Peptide binding and antigen presentation by class II histocompatibility glycoproteins.
    Jensen PE
    Biopolymers; 1997; 43(4):303-22. PubMed ID: 9316394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathways of antigen processing and presentation.
    Watts C; Powis S
    Rev Immunogenet; 1999; 1(1):60-74. PubMed ID: 11256573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Class II MHC/peptide complexes are released from APC and are acquired by T cell responders during specific antigen recognition.
    Patel DM; Arnold PY; White GA; Nardella JP; Mannie MD
    J Immunol; 1999 Nov; 163(10):5201-10. PubMed ID: 10553040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The intracellular assembly of antigenic-peptide-class II complexes.
    Pierce SK; Green JM; Faassen AE; Xu X; Song W; Cho H; Schafer P; Psaradellis T; Wagle N; Kim J
    Biomed Pept Proteins Nucleic Acids; 1995; 1(3):149-56. PubMed ID: 9346846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The dependence for leukocyte function-associated antigen-1/ICAM-1 interactions in T cell activation cannot be overcome by expression of high density TCR ligand.
    Abraham C; Griffith J; Miller J
    J Immunol; 1999 Apr; 162(8):4399-405. PubMed ID: 10201975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural principles of MHC class II antigen presentation.
    Nelson CA; Fremont DH
    Rev Immunogenet; 1999; 1(1):47-59. PubMed ID: 11256572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct observation of ligand recognition by T cells.
    Irvine DJ; Purbhoo MA; Krogsgaard M; Davis MM
    Nature; 2002 Oct; 419(6909):845-9. PubMed ID: 12397360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The HLA system, antigen processing and presentation.
    Krensky AM
    Kidney Int Suppl; 1997 Mar; 58():S2-7. PubMed ID: 9067934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MHC class II antigen processing in B cells: accelerated intracellular targeting of antigens.
    Cheng PC; Steele CR; Gu L; Song W; Pierce SK
    J Immunol; 1999 Jun; 162(12):7171-80. PubMed ID: 10358163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Compartmentalization of class II antigen presentation: contribution of cytoplasmic and endosomal processing.
    Li P; Gregg JL; Wang N; Zhou D; O'Donnell P; Blum JS; Crotzer VL
    Immunol Rev; 2005 Oct; 207():206-17. PubMed ID: 16181338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting antigen to MHC Class I and Class II antigen presentation pathways for malaria DNA vaccines.
    Dobaño C; Rogers WO; Gowda K; Doolan DL
    Immunol Lett; 2007 Aug; 111(2):92-102. PubMed ID: 17604849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD4+ T cells mature in the absence of MHC class I and class II expression in Ly-6A.2 transgenic mice.
    Henderson SC; Berezovskaya A; English A; Palliser D; Rock KL; Bamezai A
    J Immunol; 1998 Jul; 161(1):175-82. PubMed ID: 9647222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tetraspan microdomains distinct from lipid rafts enrich select peptide-MHC class II complexes.
    Kropshofer H; Spindeldreher S; Röhn TA; Platania N; Grygar C; Daniel N; Wölpl A; Langen H; Horejsi V; Vogt AB
    Nat Immunol; 2002 Jan; 3(1):61-8. PubMed ID: 11743588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Noble metals strip peptides from class II MHC proteins.
    De Wall SL; Painter C; Stone JD; Bandaranayake R; Wiley DC; Mitchison TJ; Stern LJ; DeDecker BS
    Nat Chem Biol; 2006 Apr; 2(4):197-201. PubMed ID: 16505807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bound peptide-dependent thermal stability of major histocompatibility complex class II molecule I-Ek.
    Saito K; Oda M; Sarai A; Azuma T; Kozono H
    Biochemistry; 2004 Aug; 43(31):10186-91. PubMed ID: 15287746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DM and DO shape the repertoire of peptide-MHC-class-II complexes.
    Karlsson L
    Curr Opin Immunol; 2005 Feb; 17(1):65-70. PubMed ID: 15653313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New insights in antigen processing and epitope selection: development of novel immunotherapeutic strategies for cancer, autoimmunity and infectious diseases.
    Haque A; Blum JS
    J Biol Regul Homeost Agents; 2005; 19(3-4):93-104. PubMed ID: 16602623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Small molecule modulators of MHC class II antigen presentation: mechanistic insights and implications for therapeutic application.
    Call MJ
    Mol Immunol; 2011 Sep; 48(15-16):1735-43. PubMed ID: 21676462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inefficient peptide binding by cell-surface class II MHC molecules.
    Sherman MA; Weber DA; Spotts EA; Moore JC; Jensen PE
    Cell Immunol; 1997 Nov; 182(1):1-11. PubMed ID: 9427804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The kinetic stability of MHC class II:peptide complexes is a key parameter that dictates immunodominance.
    Lazarski CA; Chaves FA; Jenks SA; Wu S; Richards KA; Weaver JM; Sant AJ
    Immunity; 2005 Jul; 23(1):29-40. PubMed ID: 16039577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.